Evaxion

Evaxion is a clinical-stage biotechnology company pioneering the use of artificial intelligence for vaccine discovery and development. Its core asset is the AI-Immunology™ platform, a suite of AI models designed to predict optimal vaccine targets for personalized cancer vaccines and next-generation infectious disease vaccines. The company has a pipeline of in-house assets ranging from preclinical to Phase 2 and is publicly traded on Nasdaq. Evaxion's approach aims to address significant unmet needs in oncology and antimicrobial resistance.

AI-Immunology™ platform: A suite of integrated AI models (PIONEER™, EDEN™, ObsERV™, RAVEN™) that predict optimal immune targets (T-cell and B-cell epitopes) for designing personalized cancer vaccines and next-generation vaccines for infectious diseases. It is clinically validated and claims to identify targets within 24 hours.

Evaxion operates in a highly competitive space with numerous companies applying AI to drug discovery (e.g., Exscientia, Recursion) and developing personalized cancer vaccines (e.g., BioNTech, Moderna, Gritstone bio). Its differentiation lies in the specific integration of its AI models focused on multiple arms of the immune system for both oncology and infectious diseases.